Phio Pharmaceuticals Corp (PHIO)

[sabaidii2]

"Buyers doing their own Laboratory Due Diligence in August, is typical of such laboratory investigations in order to be completely convinced of the validity of the Opthomalogy and Dermatology Technology in order for those Potential Buyers to justify a serious BID PRICE FOR THE PHIO TECHNOLOGY"

Oh, really? When companies are hot-to-trot, they jump on opportunity. They don't slow-walk as these potential buyers are doing.

Let us not forget how Pfizer jumped on Excaliard's scar-reduction drug back in 2011:
https://www.pfizer.com/news/press-release/press-release-detail/pfizer_to_acquire_excaliard_pharmaceuticals

==========================
RXI-109 (hypertrophic scar reduction) is a failure as it simply doesn't work well enough How do I know? No photos says it all.

And the skin-lightener? The problem is that getting the drug to penetrate deep enough into the skin was something RXI could not solve. Note that study 3 (the last one) only demonstrated proof-of-concept - not efficacy. Talk about designing an effort to fail. The obvious question - which RXI never addressed - was why did they do this?